Phase I Double-blind, Placebo-controlled Study of AZD7442

NCT04896541 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: AZD7442 300 mg IM(male)
BIOLOGICAL: AZD7442 600 mg IM (male)
BIOLOGICAL: AZD7442 300 mg IV (male and female)
BIOLOGICAL: AZD7442 1000 mg IV (male)

Sponsor

AstraZeneca